Aerovate Therapeutics, Inc.

NasdaqGM AVTE

Aerovate Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -62,213.97%

Aerovate Therapeutics, Inc. Net Income Margin is -62,213.97% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: AVTE

Aerovate Therapeutics, Inc.

CEO	Mr. Timothy P. Noyes M.B.A.
IPO Date	June 30, 2021
Location	United States
Headquarters	930 Winter Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years